NCT03611595: Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor, Other

Key Eligibility Criteria:

Gender: All
Age: 2 Years to 21 Years (Child, Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known unstable CNS metastases who require steroids- see trial for details; Patients who had prior therapy with cabozantinib

Comments are closed.

Up ↑